In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 4, 2008, Pages 762-765

  O'Connor, Rachael ^a   Baines, Simon D ^a   Freeman, Jane ^b   Wilcox, Mark H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

C. difficile; Metronidazole; Oritavancin; Ribotyping; Susceptibility; Vancomycin

Indexed keywords

METRONIDAZOLE; ORITAVANCIN; POLYSORBATE 80; VANCOMYCIN;

AGAR MEDIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BROTH DILUTION; CLONAL SPECIES; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG POTENCY; GENOTYPE; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; RIBOTYPING;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CULTURE MEDIA; DNA FINGERPRINTING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENOTYPE; GLYCOPEPTIDES; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; RIBOTYPING; VANCOMYCIN;

EID: 52949105801     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn276     Document Type: Article

References (19)

1. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 Suppl C: 13-9.
2. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 Suppl C: 41-6.
3. Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis. Lancet 1983; ii: 1043-6.
4. Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-8.
5. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficiler. response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673-9.
6. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90.
7. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
8. Arhin FF, Sarmiento I, Belley A et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces - implications for susceptibility testing. Antimicrob Agents Chemother 2008; 52 1597-603.
9. Arhin FF, Sarmiento I, Parr TR Jr et al. Influence of polysorbate-80 on susceptibility of Gram-positive bacteria to oritavancin. In: Abstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007. Abstract P-827, p. 102. European Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
10. Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001; 47: 244-6.
11. Jousimies-Somer H, Summanen P, Citron D et al. Introduction to anaerobic bacteriology. In: Wadsworth-KTL Anaerobic Bacteriology Manual, 6th edn. Belmont, California: Star Pubishing Company, 2002; 1-22.
12. Kuijper EJ, van Dissel JT, Wilcox MH. Clostridium, difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 2007; 20: 376-83.
13. Blosser RS, Karlowsky JA, Loutit JS et al. Evaluation of agar based susceptibility testing of oritavancin against Gram-positive cocci. In: Abstracts of the One hundred and third Meeting of the American Society for Microbiology, Washington, DC, 2003. Abstract C-70, American Society for Microbiology, Washington, DC, USA.
14. Wilcox MH, Winstanley TG, Spencer RC. Binding of teicoplanin and vancomycin to polymer surfaces. J Antimicrob Chemother 1994; 33 431-41.
15. Boman HG, Wade D, Boman IA et al. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett 1989; 259: 103-6.
16. Moeck G, Draghi DC, Amin FF et al. In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007, Abstract E-1612, p. 204. American Society for Microbiology, Washington, DC, USA.
17. Anonymous. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. Health Protection Report 2008; 2: 18 January.
18. Baines SD, O'Connor R, Fawley WN et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008. Abstract O-463. European Society for Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
19. O'Connor R, Freeman J, Baines SD et al. In vitro susceptibility of genotypically distinct Clostridium difficile strains to oritavancin. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007 Abstract E-1618, p. 206. American Society for Microbiology, Washington, DC, USA.